If you’ve been keeping up with your RxView reading the last few weeks, you’ve heard me talk an awful lot about the rule recently proposed by the Centers for Medicare and Medicaid Services (CMS) to improve the quality and performance of Medicaid managed care organizations. We see this rule as a huge opportunity to make a significant impact in improving healthcare quality and lowering healthcare costs for many Americans.

Last week we submitted our comments to CMS on the rule and recommended changes to strengthen the Medicaid drug benefit within managed care programs. (View the full text of our comment letter) As I’ve noted, we strongly believe that the active use of these data on post-approval adverse drug events will help Medicaid managed care programs increase transparency and make better prescription drug decisions. After all, reducing costs and improving outcomes is a win-win for the states and for tens of millions of Medicaid patients.

I’ve shared our recommendations to CMS with friends and colleagues, as well as key policy makers, such as the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee, the Department of Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation (ASPE), and Medicaid and CHIP Payment and Access Commission (MacPAC). I’ve also heard from a number of people who read our letter and offered suggestions on how to strengthen the case to incorporate the use of more data into Medicaid managed care’s prescription drug program.

It’s clear we’ve struck a chord. We’re not alone in wanting to affect change to better our healthcare system. Chances are, if you’re reading this now, you agree.

If you want to join us and take action to improve patient safety and lower healthcare costs, let your voice be heard! There are two ways you can get involved: 

1. Write to your elected officials in Congress (download a template email letter), urging them to ask CMS to make evaluation of adverse drug event data a requirement for drug coverage decisions made by Medicaid and Medicare prescription drug plans. Search and find contact information for your Senators/Representatives.

2. Submit your own comment on the proposed rule



Subscribe to Drug Safety Monitor

Brian Overstreet

Brian Overstreet


Robert Kyle Linkedin twitter

Brian Overstreet

Written by Brian Overstreet